PRODUCT INFORMATION Roxithromycin
... Theophylline: A study in normal subjects, concurrently administered roxithromycin and theophylline, has shown some increase in the plasma concentration of the latter. While a change in dosage is usually not required, patients with high levels of theophylline at commencement of treatment should have ...
... Theophylline: A study in normal subjects, concurrently administered roxithromycin and theophylline, has shown some increase in the plasma concentration of the latter. While a change in dosage is usually not required, patients with high levels of theophylline at commencement of treatment should have ...
ADVANCE IN TREATMENT OF TYPE 2 D.M.
... • Dulaglutide was non-inferior to daily liraglutide in one study and superior to the oral dipeptidyl peptidase–4 (DPP4) inhibitor sitagliptin in another. • Adverse effects included nausea, diarrhea, vomiting, abdominal pain, and decreased appetite. ...
... • Dulaglutide was non-inferior to daily liraglutide in one study and superior to the oral dipeptidyl peptidase–4 (DPP4) inhibitor sitagliptin in another. • Adverse effects included nausea, diarrhea, vomiting, abdominal pain, and decreased appetite. ...
about xarelto clinical studies
... RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto® (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE) after elective (planned) hip or knee replacement surgery. RECORD comprised four pivotal Phase III clinical trials that compared ‘X ...
... RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto® (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE) after elective (planned) hip or knee replacement surgery. RECORD comprised four pivotal Phase III clinical trials that compared ‘X ...
this PDF file - Journal of Pharmaceutical Care
... pharmacist in initial dosing and 16 requests for checking vancomycin trough level by the clinical pharmacist of the ward resulted in changing the drug dose in 12 patients in this study. Another common intervention that was done by the clinical pharmacist in our research, was adding a drug to the tre ...
... pharmacist in initial dosing and 16 requests for checking vancomycin trough level by the clinical pharmacist of the ward resulted in changing the drug dose in 12 patients in this study. Another common intervention that was done by the clinical pharmacist in our research, was adding a drug to the tre ...
Prescribing Information
... of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, ...
... of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, ...
adrenoceptor agonist sympathomimetics
... platelets binding to fibrinogen and von Willebrand factor, and consequently inhibiting platelet aggregation. It inhibits all the pathways of platelet activation (Final common pathway). ...
... platelets binding to fibrinogen and von Willebrand factor, and consequently inhibiting platelet aggregation. It inhibits all the pathways of platelet activation (Final common pathway). ...
Medical Pressure
... amlodipine, nicardipine) act mainly on smooth muscle and used as vasodilators Verapamil act more on the myocardium and used as antiarrhythmic drug ...
... amlodipine, nicardipine) act mainly on smooth muscle and used as vasodilators Verapamil act more on the myocardium and used as antiarrhythmic drug ...
Oral thrush in baby - North Derbyshire CCG
... features and patient preferences. However, NOACs are expensive and it is vital that they are prescribed and taken correctly to make sure that their potential benefits are realised. A clinician may choose to initiate dabigatran, rivaroxaban, apixaban or edoxaban for any patient within the NICE TA cri ...
... features and patient preferences. However, NOACs are expensive and it is vital that they are prescribed and taken correctly to make sure that their potential benefits are realised. A clinician may choose to initiate dabigatran, rivaroxaban, apixaban or edoxaban for any patient within the NICE TA cri ...
Pharmacology of Renin
... (under the name plasma kininase) inactivates bradykinin, a potent vasodilator, which works at least in part by stimulating release of nitric oxide and prostacyclin. The hypotensive activity of captopril results both from an inhibitory action on the renin-angiotensin system and a stimulating action o ...
... (under the name plasma kininase) inactivates bradykinin, a potent vasodilator, which works at least in part by stimulating release of nitric oxide and prostacyclin. The hypotensive activity of captopril results both from an inhibitory action on the renin-angiotensin system and a stimulating action o ...
April 2007 FDA Announces Drug Withdrawals, Recalls
... marketing of Zelnorm based on the recent findings of an increase in risk of serious cardiovascular adverse events associated with its use. Zelnorm is approved for short-term treatment of women with irritable bowel syndrome with constipation and for patients younger than 65 years with chronic constip ...
... marketing of Zelnorm based on the recent findings of an increase in risk of serious cardiovascular adverse events associated with its use. Zelnorm is approved for short-term treatment of women with irritable bowel syndrome with constipation and for patients younger than 65 years with chronic constip ...
Anticoagulation in patients with impaired renal function and with
... risk of bleeding for patients with renal insufficiency receiving LMWH (21, 22). Twelve studies including almost 5000 patients found major bleeding in 5% of patients with CrCl < 30 ml/min, compared to 2.4% in patients with CrCl > 30 ml/min (odds ratio = 2.2, p = 0.013). In the ExTRACT-TIMI 25 trial t ...
... risk of bleeding for patients with renal insufficiency receiving LMWH (21, 22). Twelve studies including almost 5000 patients found major bleeding in 5% of patients with CrCl < 30 ml/min, compared to 2.4% in patients with CrCl > 30 ml/min (odds ratio = 2.2, p = 0.013). In the ExTRACT-TIMI 25 trial t ...
L6- Teratogens and drugs of abuse
... • The most commonly abused drugs are alcohol; cocaine; nicotine; marijuana; amphetamines; barbiturates; opium alkaloids, benzodiazepines. • Drug abuse may lead to organ damage, addiction, and disturbance of behavior. ...
... • The most commonly abused drugs are alcohol; cocaine; nicotine; marijuana; amphetamines; barbiturates; opium alkaloids, benzodiazepines. • Drug abuse may lead to organ damage, addiction, and disturbance of behavior. ...
SW_QA226_1_Noacs_Complementary_Medicines_Final
... Apixaban is a direct, selective, reversible factor Xa inhibitor. It is predominantly metabolised by CYP3A4/5 with minor involvement of other enzymes e.g.CYP1A2 and CYP2J2. Therefore concomitant administration of potent CYP3A4 inhibitors or inducers may affect apixaban concentrations [5,12]. Apixaban ...
... Apixaban is a direct, selective, reversible factor Xa inhibitor. It is predominantly metabolised by CYP3A4/5 with minor involvement of other enzymes e.g.CYP1A2 and CYP2J2. Therefore concomitant administration of potent CYP3A4 inhibitors or inducers may affect apixaban concentrations [5,12]. Apixaban ...
Inhibition of platelet aggregability by losartan in essential hypertension
... because it occurs at doses 1,000-fold higher than those required for binding to vascular AT1 receptors 8, 9, 13. Although the argument has been posed that chronic therapy with losartan (80 to 120 mg oral dose) may expose platelets to circulating drug concentrations amounting to 1 µmol/L 8, 13 this s ...
... because it occurs at doses 1,000-fold higher than those required for binding to vascular AT1 receptors 8, 9, 13. Although the argument has been posed that chronic therapy with losartan (80 to 120 mg oral dose) may expose platelets to circulating drug concentrations amounting to 1 µmol/L 8, 13 this s ...
Express Scripts Drug Information & Wellness Center Pharmacy in the News:
... Dosing: 8.4 g patiromer once daily starting dose. Monitor ...
... Dosing: 8.4 g patiromer once daily starting dose. Monitor ...
Prescribing Information
... Drugs that inhibit CYP1A2 and CYP3A4 are expected to alter the metabolism of tasimelteon. Fluvoxamine (strong CYP1A2 inhibitor): the AUC0-inf and Cmax of tasimelteon increased by 7-fold and 2-fold, respectively, when co-administered with fluvoxamine 50 mg (after 6 days of fluvoxamine 50 mg per day) ...
... Drugs that inhibit CYP1A2 and CYP3A4 are expected to alter the metabolism of tasimelteon. Fluvoxamine (strong CYP1A2 inhibitor): the AUC0-inf and Cmax of tasimelteon increased by 7-fold and 2-fold, respectively, when co-administered with fluvoxamine 50 mg (after 6 days of fluvoxamine 50 mg per day) ...
Nimesulide (PDF, 210KB, File is accessible)
... Cardiovascular and cerebrovascular effects Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy. Clinical trial and epidemiologica ...
... Cardiovascular and cerebrovascular effects Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy. Clinical trial and epidemiologica ...
SINAREST-LEVO TABLETS
... Levocetirizine is an orally active and selective H1-receptor antagonist. It is the Renantiomer of cetirizine, a racemic compound with antihistaminic properties. Mechanism of Action In vitro studies have revealed that levocetirizine has an affinity for the human H1receptor, that is 2-fold higher than ...
... Levocetirizine is an orally active and selective H1-receptor antagonist. It is the Renantiomer of cetirizine, a racemic compound with antihistaminic properties. Mechanism of Action In vitro studies have revealed that levocetirizine has an affinity for the human H1receptor, that is 2-fold higher than ...
Anti-platelet agents
... that can be administered orally, and absorption is approximately 8090% • Thienopyridines are prodrugs that must be activated in the liver ...
... that can be administered orally, and absorption is approximately 8090% • Thienopyridines are prodrugs that must be activated in the liver ...
RIFAMPICIN in combination with Isoniazid RIFAMPICIN
... Rifampicin is well tolerated by most patients at currently recommended doses, although gastrointestinal tolerance can be unacceptably severe. Other adverse effects (skin rashes, fever, influenza-like syndrome and thrombocytopenia) are more likely to occur with intermittent administration. Exfoliativ ...
... Rifampicin is well tolerated by most patients at currently recommended doses, although gastrointestinal tolerance can be unacceptably severe. Other adverse effects (skin rashes, fever, influenza-like syndrome and thrombocytopenia) are more likely to occur with intermittent administration. Exfoliativ ...
AEDs - BC Epilepsy Society
... • Mild and moderate renal impairment: No dose adjustment needed – Maximum dose of 300mg/day recommended for patients with severe renal impairment (CLCR ≤30 mL/min) or end-stage renal disease. – Supplement of up to 50% of the divided daily dose directly after the end of hemodialysis is recommended. – ...
... • Mild and moderate renal impairment: No dose adjustment needed – Maximum dose of 300mg/day recommended for patients with severe renal impairment (CLCR ≤30 mL/min) or end-stage renal disease. – Supplement of up to 50% of the divided daily dose directly after the end of hemodialysis is recommended. – ...
Analgesia in Patients with Impaired Renal Function – Formulary
... Nefopam is an atypical analgesic which can be used as an adjuvant in mildmoderate pain. It is not renally excreted or nephrotoxic so can be used safely in patients with renal impairment. Side effects include gastrointestinal upset and confusion, and it should be avoided in patients with epilepsy. Ef ...
... Nefopam is an atypical analgesic which can be used as an adjuvant in mildmoderate pain. It is not renally excreted or nephrotoxic so can be used safely in patients with renal impairment. Side effects include gastrointestinal upset and confusion, and it should be avoided in patients with epilepsy. Ef ...
Lecture 7 - Antidepressants new 11-12
... Too long (3-11 days): Fluoxetine (Prozac) Moderate length (~24hr): Sertraline, Paroxetine, Citalopram. Metabolism: P450 then conjugation They are enzyme inhibitors Weak inhibitors < Sertraline, Citalopram interaction Strong inhibitors > Fluoxetine, Paroxetine metabolism of TCA, neurolep ...
... Too long (3-11 days): Fluoxetine (Prozac) Moderate length (~24hr): Sertraline, Paroxetine, Citalopram. Metabolism: P450 then conjugation They are enzyme inhibitors Weak inhibitors < Sertraline, Citalopram interaction Strong inhibitors > Fluoxetine, Paroxetine metabolism of TCA, neurolep ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.